# Nurotron Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nurotron-biotechnology

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Website: www.nurotron.com/
- Total disclosed funding: $16M
- Latest round: Series D (Nov 1, 2016)
- Investors on record: 7

## About

Founded in 2006 and based in Hangzhou, China, Zhejiang Nurotron Biotechnology Co., Ltd., trading under the name Nurotron, develops and manufactures implantable neuro-electronic medical devices. The company specializes in neural stimulation technologies with a product portfolio that includes cochlear implants, auditory brainstem implants, visual prosthetics, and implantable sacral nerve stimulation systems. Based in Hangzhou, China and established in 2006, Zhejiang Nurotron Biotechnology Co., Ltd. develops neural stimulation-based medical devices. It has participated in multiple national-level R&D programs under China’s Five-Year Plans and was twice awarded the National Science and Technology Progress Award (2015, 2024). As of 2024, more than 20,000 individuals across Asia, Europe, and the Americas have received Nurotron cochlear implants. In May 2025, Nurotron Biotechnology received a round of investment from Hangzhou Capital Investment and Yuhang Jinkong to help strengthen its presence in the global market. Nurotron provides implantable neuro-electronic products including cochlear implant systems, auditory brainstem implant systems, artificial vision prosthetics, and sacral nerve stimulation systems.  Nurotron Biotechnology generates revenue through the sale of its neural implant systems and related surgical and rehabilitation services to hospitals and medical distributors in domestic and international markets. Following its latest 2025 round of funding, the company aims to advance its product pipeline and production capacity while deepening its integration into the medical device ecosystem

## Funding rounds

- Series D, Nov 1, 2016 — Efung Capital, Chinahope Asset Management
- Series C, Dec 24, 2013, $16M — Kleiner Perkins, Detong Capital
- Series B, Oct 31, 2011 — Sinowisdom, Tianyi Investment Group
- Series B, Jan 1, 2011 — Qiming Venture Partners
- Series A, Jan 1, 2009 — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series B
- Tianyi Investment Group (https://capitalatlas.ai/funds/tianyi-investment-group) — Series B
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series C
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series D
- Chinahope Asset Management (https://capitalatlas.ai/funds/chinahope-asset-management) — Series D